Search

Your search keyword '"Adamson, Peter C"' showing total 723 results
Start Over Author "Adamson, Peter C"
723 results on '"Adamson, Peter C"'

2. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group

Author

Miller, Tamara P, Getz, Kelly D, Li, Yimei, Demissei, Biniyam G, Adamson, Peter C, Alonzo, Todd A, Burrows, Evanette, Cao, Lusha, Castellino, Sharon M, Daves, Marla H, Fisher, Brian T, Gerbing, Robert, Grundmeier, Robert W, Krause, Edward M, Lee, Judy, Lupo, Philip J, Rabin, Karen R, Ramos, Mark, Scheurer, Michael E, Wilkes, Jennifer J, Winestone, Lena E, Hawkins, Douglas S, Gramatges, M Monica, and Aplenc, Richard

Published
2022
Full Text
View/download PDF

3. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop

Author

Hingorani, Pooja, Janeway, Katherine, Crompton, Brian D, Kadoch, Cigall, Mackall, Crystal L, Khan, Javed, Shern, Jack F, Schiffman, Joshua, Mirabello, Lisa, Savage, Sharon A, Ladanyi, Marc, Meltzer, Paul, Bult, Carol J, Adamson, Peter C, Lupo, Philip J, Mody, Rajen, DuBois, Steven G, Parsons, D Williams, Khanna, Chand, Lau, Ching, Hawkins, Douglas S, Randall, R Lor, Smith, Malcolm, Sorensen, Poul H, Plon, Sharon E, Skapek, Stephen X, Lessnick, Stephen, Gorlick, Richard, and Reed, Damon R

Subjects
Orphan Drug, Rare Diseases, Pediatric Cancer, Pediatric, Pediatric Research Initiative, Cancer, Animals, Clinical Protocols, Drug Evaluation, Preclinical, Epigenomics, Genomics, Germ-Line Mutation, Humans, Precision Medicine, Recurrence, Sarcoma, Translational Research, Biomedical, Xenograft Model Antitumor Assays, Pediatric sarcoma, genomics, molecular profiling, patient derived xenografts, precision medicine, sarcoma biology, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Sarcomas are a rare subgroup of pediatric cancers comprised of a variety of bone and soft-tissue tumors. While significant advances have been made in improving outcomes of patients with localized pediatric sarcomas since the addition of systemic chemotherapy to local control many decades ago, outcomes for patients with metastatic and relapsed sarcoma remain poor with few novel therapeutics identified to date. With the advent of new technologies to study cancer genomes, transcriptomes and epigenomes, our understanding of sarcoma biology has improved tremendously in a relatively short period of time. However, much remains to be accomplished in this arena especially with regard to translating all of this new knowledge to the bedside. To this end, a meeting was convened in Philadelphia, PA, on April 18, 2015 sponsored by the QuadW foundation, Children's Oncology Group and CureSearch for Children's Cancer that brought together sarcoma clinicians and scientists from North America to review the current state of pediatric sarcoma biology and ongoing/planned genomics based clinical trials in an effort to identify and bridge knowledge gaps that continue to exist at present. At the conclusion of the workshop, three key objectives that would significantly further our understanding of sarcoma were identified and a proposal was put forward to develop an all-encompassing pediatric sarcoma biology protocol that would address these specific needs. This review summarizes the proceedings of the workshop.

Published
2016

4. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212)

Author

Greengard, Emily, Mosse, Yael P., Liu, Xiaowei, Minard, Charles G., Reid, Joel M., Voss, Stephan, Wilner, Keith, Fox, Elizabeth, Balis, Frank, Blaney, Susan M., Adamson, Peter C., and Weigel, Brenda J.

Published
2020
Full Text
View/download PDF

5. Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

Author

Khanna, Chand, Fan, Timothy M, Gorlick, Richard, Helman, Lee J, Kleinerman, Eugenie S, Adamson, Peter C, Houghton, Peter J, Tap, William D, Welch, Danny R, Steeg, Patricia S, Merlino, Glenn, Sorensen, Poul HB, Meltzer, Paul, Kirsch, David G, Janeway, Katherine A, Weigel, Brenda, Randall, Lor, Withrow, Stephen J, Paoloni, Melissa, Kaplan, Rosandra, Teicher, Beverly A, Seibel, Nita L, Smith, Malcolm, Üren, Aykut, Patel, Shreyaskumar R, Trent, Jeffrey, Savage, Sharon A, Mirabello, Lisa, Reinke, Denise, Barkaukas, Donald A, Krailo, Mark, and Bernstein, Mark

Subjects
Pediatric Cancer, Pediatric Research Initiative, Pediatric, Orphan Drug, Rare Diseases, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Animals, Antineoplastic Agents, Bone Neoplasms, Disease Models, Animal, Disease Progression, Dogs, Drug Evaluation, Preclinical, Humans, Osteosarcoma, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression. To advance this agenda, a meeting of key opinion leaders and experts in the metastasis and osteosarcoma communities was convened in Bethesda, Maryland. The goal of this meeting was to provide a "Perspective" that would establish a preclinical translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype. Although focused on osteosarcoma, the need for this perspective is shared among many cancer types. The consensus achieved from the meeting included the following: the biology of metastatic progression is associated with metastasis-specific targets/processes that may not influence grossly detectable lesions; targeting of metastasis-specific processes is feasible; rigorous preclinical data are needed to support translation of metastasis-specific agents into human trials where regression of measurable disease is not an expected outcome; preclinical data should include an understanding of mechanism of action, validation of pharmacodynamic markers of effective exposure and response, the use of several murine models of effectiveness, and where feasible the inclusion of the dog with naturally occurring osteosarcoma to define the activity of new drugs in the micrometastatic disease setting.

Published
2014

7. Supplementary Figure 2A from A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Author

Widemann, Brigitte C., primary, Kim, AeRang, primary, Fox, Elizabeth, primary, Baruchel, Sylvain, primary, Adamson, Peter C., primary, Ingle, Ashish M., primary, Bender, Julia Glade, primary, Burke, Michael, primary, Weigel, Brenda, primary, Stempak, Diana, primary, Balis, Frank M., primary, and Blaney, Susan M., primary

Published
2023
Full Text
View/download PDF

8. Supp Table 1 from Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Author

Foster, Jennifer H., primary, Voss, Stephan D., primary, Hall, David C., primary, Minard, Charles G., primary, Balis, Frank M., primary, Wilner, Keith, primary, Berg, Stacey L., primary, Fox, Elizabeth, primary, Adamson, Peter C., primary, Blaney, Susan M., primary, Weigel, Brenda J., primary, and Mossé, Yael P., primary

Published
2023
Full Text
View/download PDF

9. CCR Translation for This Article from A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Author

Bender, Julia Glade, primary, Blaney, Susan M., primary, Borinstein, Scott, primary, Reid, Joel M., primary, Baruchel, Sylvain, primary, Ahern, Charlotte, primary, Ingle, Ashish M., primary, Yamashiro, Darrell J., primary, Chen, Alice, primary, Weigel, Brenda, primary, Adamson, Peter C., primary, and Park, Julie R., primary

Published
2023
Full Text
View/download PDF

10. Model‐Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy.

Author

Mizuno, Kana, Capparelli, Edmund V., Fukuda, Tsuyoshi, Dong, Min, Adamson, Peter C., Blumer, Jeffery L., Cnaan, Avital, Clark, Peggy O., Reed, Michael D., Shinnar, Shlomo, Vinks, Alexander A., and Glauser, Tracy A.

Subjects
CHILDHOOD epilepsy, CLINICAL trials, RANDOMIZED controlled trials, MONTE Carlo method, VALPROIC acid
Abstract

Ethosuximide was identified as the optimal option for new‐onset childhood absence epilepsy (CAE) in a randomized, two‐phase dose escalation comparative effectiveness trial of ethosuximide, lamotrigine, and valproic acid. However, 47% of ethosuximide initial monotherapy participants experienced short‐term treatment failure. This study aimed to characterize the initial monotherapy ethosuximide exposure‐response relationship and to propose model‐informed precision dosing guidance. Dose titration occurred over a 16–20‐week period until patients experienced seizure freedom or intolerable side effects. Subjects with initial monotherapy failure were randomized to one of the other two medications and dose escalation was repeated. A population pharmacokinetic model was created using plasma concentration data (n = 1,320), collected at 4‐week intervals from 211 unique participants during both the initial and second monotherapy phases. A logistic regression analysis was performed on the initial monotherapy cohort (n = 103) with complete exposure‐response data. Eighty‐four participants achieved seizure freedom with a wide range of ethosuximide area under the curves (AUC) ranging from 420 to 2,420 μg·h/mL. AUC exposure estimates for achieving a 50% and 75% probability of seizure freedom were 1,027 and 1,489 μg·h/mL, respectively, whereas the corresponding cumulative frequency of intolerable adverse events was 11% and 16%. Monte Carlo Simulation indicated a daily dose of 40 and 55 mg/kg to achieve 50% and 75% probability of seizure freedom in the overall population, respectively. We identified the need for adjusted mg/kg dosing in different body weight cohorts. This ethosuximide proposed model‐informed precision dosing guidance to achieve seizure freedom carries promise to optimize initial monotherapy success for patients with CAE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Reply to R. Lakhotia et al

Author

Burke, G.A. Amos, primary, Minard-Colin, Veronique, additional, Aupérin, Anne, additional, Alexander, Sarah, additional, Pillon, Marta, additional, Delgado, Rafael, additional, Zsíros, József, additional, Uyttebroeck, Anne, additional, Dartigues, Peggy, additional, Miles, Rodney R., additional, Kazanowska, Bernarda, additional, Chiang, Alan K., additional, Haouy, Stéphanie, additional, Bollard, Catherine M., additional, Csoka, Monika, additional, Wheatley, Keith, additional, Barkauskas, Donald A., additional, Adamson, Peter C., additional, Vassal, Gilles, additional, Patte, Catherine, additional, and Gross, Thomas G., additional

Published
2022
Full Text
View/download PDF

14. ACCELERATE – Five years accelerating cancer drug development for children and adolescents

Author

Pearson, Andrew D.J., primary, Weiner, Susan L., additional, Adamson, Peter C., additional, Karres, Dominik, additional, Reaman, Gregory, additional, Rousseau, Raphaël, additional, Blanc, Patricia, additional, Norga, Koen, additional, Skolnik, Jeffrey, additional, Kearns, Pam, additional, Scobie, Nicole, additional, Barry, Elly, additional, Marshall, Lynley V., additional, Knox, Leona, additional, Caron, Hubert, additional, Wariabharaj, Darshan, additional, Pappo, Alberto, additional, DuBois, Steven G., additional, Gore, Lia, additional, Kieran, Mark, additional, Weigel, Brenda, additional, Fox, Elizabeth, additional, Nysom, Karsten, additional, de Rojas, Teresa, additional, and Vassal, Gilles, additional

Published
2022
Full Text
View/download PDF

20. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial

Author

Burke, G. A. Amos, primary, Minard-Colin, Veronique, additional, Aupérin, Anne, additional, Alexander, Sarah, additional, Pillon, Marta, additional, Delgado, Rafael, additional, Zsíros, József, additional, Uyttebroeck, Anne, additional, Dartigues, Peggy, additional, Miles, Rodney R., additional, Kazanowska, Bernarda, additional, Chiang, Alan K., additional, Haouy, Stéphanie, additional, Bollard, Catherine M., additional, Csoka, Monika, additional, Wheatley, Keith, additional, Barkauskas, Donald A., additional, Adamson, Peter C., additional, Vassal, Gilles, additional, Patte, Catherine, additional, and Gross, Thomas G., additional

Published
2021
Full Text
View/download PDF

24. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report

Author

Su, Jack M, primary, Kilburn, Lindsay B, additional, Mansur, David B, additional, Krailo, Mark, additional, Buxton, Allen, additional, Adekunle, Adesina, additional, Gajjar, Amar, additional, Adamson, Peter C, additional, Weigel, Brenda, additional, Fox, Elizabeth, additional, Blaney, Susan M, additional, and Fouladi, Maryam, additional

Published
2021
Full Text
View/download PDF

25. Abstract 631: Germline cancer predisposition results from the National Cancer Institute - Children's Oncology Group (NCI-COG) Pediatric MATCH Trial

Author

Scollon, Sarah, primary, Plon, Sharon E., additional, Joffe, Steven, additional, Biegel, Jaclyn A., additional, Kulkarni, Shashikant, additional, Miles, George, additional, Patton, David, additional, Coffey, Brent, additional, Williams, Paul M., additional, Tsongalis, Gregory J., additional, Routbort, Mark J., additional, Gastier-Foster, Julie M., additional, Saguilig, Lauren, additional, Piao, Jin, additional, Alonzo, Todd A., additional, Janeway, Katherine A., additional, Adamson, Peter C., additional, Mooney, Margaret, additional, Tricoli, James V., additional, Seibel, Nita L., additional, and Parsons, Donald W., additional

Published
2021
Full Text
View/download PDF

38. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy

Author

Cnaan, Avital, Glauser, Tracy A., Shinnar, Shlomo, Hirtz, Deborah G., Dlugos, Dennis, Masur, David, Clark, Peggy O., Capparelli, Edmund V., and Adamson, Peter C.

Subjects
Ethosuximide -- Usage, Ethosuximide -- Health aspects, Absence epilepsy -- Care and treatment, Lamotrigine -- Usage, Lamotrigine -- Health aspects, Divalproex -- Usage, Divalproex -- Health aspects, Valproic acid -- Usage, Valproic acid -- Health aspects
Abstract

The study aims to evaluate and compare the efficacy of the use of ethosuximide, valproic acid, and lamotrigine in the treatment of childhood absence epilepsy. The results indicate that ethosuximide and valproic acid are more effective, and that ethosuximide is associated with fewer adverse effects.

Published
2010

47. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Author

Foster, Jennifer H., primary, Voss, Stephan D., additional, Hall, David C., additional, Minard, Charles G., additional, Balis, Frank M., additional, Wilner, Keith, additional, Berg, Stacey L., additional, Fox, Elizabeth, additional, Adamson, Peter C., additional, Blaney, Susan M., additional, Weigel, Brenda J., additional, and Mossé, Yael P., additional

Published
2021
Full Text
View/download PDF

48. Population Pharmacokinetic Investigation of Actinomycin-D in Children and Young Adults

Author

Mondick, John T., Gibiansky, Leonid, Gastonguay, Marc R., Skolnik, Jeffrey M., Cole, Michael, Veal, Gareth J., Boddy, Alan V., Adamson, Peter C., and Barrett, Jeffrey S.

Subjects
Pharmacokinetics -- Research, Dactinomycin -- Dosage and administration -- Research, Health, Research, Dosage and administration
Abstract

Keywords: Actinomycin-D; pharmacokinetics; pediatrics 35 Quantitative Clinical PharmacologyPopulation Pharmacokinetic Investigation of Actinomycin-D in Children and Young Adults SAGE Publications, Inc.200810.1177/0091270007310383 John T.Mondick PhD Division of Clinical Pharmacology and Therapeutics, The [...]

Published
2008
Full Text
View/download PDF

49. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Author

Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, Brichard, Bénédicte, Clinical sciences, Growth and Development, Pediatrics, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique

Subjects
Oncology, Male, Pediatrics, medicine.medical_treatment, Lymphoma, B-Cell/drug therapy, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Rituximab/administration & dosage, Antineoplastic Agents, Immunological, 0302 clinical medicine, Neutropenia/chemically induced, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Child, Infusions, Intravenous, Medicine(all), General Medicine, Progression-Free Survival, Mature B-Cell Non-Hodgkin's Lymphoma, Rituximab, Female, Lymph, medicine.drug, medicine.medical_specialty, Lymphoma, B-Cell, Neutropenia, Adolescent, Child, preschool, Infections/etiology, MEDLINE, Infections, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cancer, medicine.disease, Lymphoma, Clinical trial, business, Follow-Up Studies
Abstract

BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS: We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS: Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P = 0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P = 0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS: Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, NCT01516580.).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results